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Abstract 
The incidence of obesity has reached an all-time high and this increase 
is observed worldwide. There is a growing need to understand all of the 
factors that contribute to obesity in order to effectively treat and prevent 
it and associated comorbidities. The obesogen hypothesis proposes 
that there are chemicals in our environment termed “obesogens” that 
can impact individual susceptibility to obesity and thus help explain the 
recent large increases in obesity. This review discusses current 
advances in our understanding of how obesogens act to impact health 
and obesity susceptibility. Newly discovered obesogens, and potential 
obesogens are discussed, together with future directions for research 
that may help to reduce the impact of these pervasive chemicals.  
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The Obesity pandemic 
Obesity is a pandemic that has reached worldwide proportions, 
affecting essentially every country (1). The most dramatic increase in 
obesity incidence has occurred over the past five decades. 
Approximately 39.6% of U.S. adults were characterized as obese in 
2016 compared to 13.4% in 1980 (2). Even more alarming, the 
incidence of obesity in children have also been increasing, with 18.5% 
of U.S. children being characterized as obese in 2016 compared to just 
4% before 1980 (2). In some countries, the prevalence of childhood 
obesity exceeds that of adults (3). Obesity and high body mass index 
(BMI) are not just cosmetic concerns, but are also associated with 
comorbidities such as increased risk for heart disease, type 2 diabetes 
and other metabolic diseases, cancers, and have contributed to 
approximately 4 million deaths worldwide between 1980 and 2015 (3). 
There is an urgent need to understand all of the factors contributing to 
obesity to best implement effective prevention and treatment 
approaches that have so far proved elusive.  
The obesogen hypothesis 
The predominant medical explanation continues to be that obesity is 
the result of a simple imbalance between excessive calorie intake and 
insufficient energy expenditure – the energy balance or “calories in, 
calories out” model. However, recent studies have demonstrated that 
this simple paradigm cannot explain the increase in BMI seen in recent 
years. A study analyzing NHANES data compared BMI between U.S. 
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adults in 1988 and 2006 and found a 2.3 kg/m2 increase in adult BMI in 
2006 compared with 1988, even at the same amount of caloric intake 
and energy expenditure (4). Moreover, the quality of carbohydrate 
calories consumed (high vs. low glycemic load) appears to be more 
important than the total quantity of calories consumed (5,6). Genetics is 
widely believed to be associated with obesity; however, known gene 
variants can only explain 2.7% of the individual variation in BMI (7). 
Therefore, the two most commonly given explanations - genetics and 
energy balance - cannot fully explain the substantial increases in 
obesity incidence observed worldwide. 
Multiple environmental factors can impact obesity susceptibility 
(reviewed in 8,9). These include the gut microbiome composition 
(10,11), stress (12), and disrupted circadian rhythms (13), to name a 
few. Environmental stressors experienced during fetal development 
have significant impacts on obesity susceptibility later in life. For 
example, mothers that were in their first and second trimester of 
pregnancy during the Dutch Hunger Winter of 1944-1945 gave birth to 
children that were predisposed to obesity later in life compared to 
mothers not exposed to famine during pregnancy (14). Maternal 
smoking during pregnancy was also shown to lead to a predisposition 
toward obesity later in life for the prenatally exposed children (reviewed 
in 15). 
In 2003, Jerry Heindel put endocrine disrupting chemicals (EDCs) and 
obesity on the same map for the first time (16). His idea followed from 
a proposal originally made by Paula Baillie-Hamilton that increased 
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chemical usage since World War II was responsible for the rapid 
increase in obesity over the same time period (17). While it was not 
justifiable to link increased chemical use, per se, to obesity, Heindel’s 
proposal that EDCs might be influencing obesity was reasonable 
because nearly every aspect of the control of appetite, satiety, 
metabolism and fat storage is regulated by the endocrine system. 
Heindel’s proposal eventually ignited research in the area of obesity 
among researchers already working on EDCs (reviewed in 18).  
The idea of EDCs as factors in obesity did not crystallize until it was 
recognized that certain EDCs could activate nuclear hormone 
receptors important for the development of white adipocytes, such as 
peroxisome proliferator-activated receptor gamma (PPARγ) (19). 
Further support came from the findings that EDCs such as tributyltin 
(TBT) could lead to increased adipogenesis in cell culture models (20-
22), bind to and activate PPARγ and its heterodimeric partner, the 9-cis 
retinoic acid receptor (RXR), in vitro (21,22), and lead to increased 
adiposity in vivo (22). The identification of chemicals that activated 
PPARγ to promote adipocyte differentiation and white adipose tissue 
(WAT) accumulation led to the coining of the term “obesogen” (23). 
Obesogens were defined functionally as chemicals that lead to 
increased WAT accumulation, in vivo, after exposure. The 
environmental obesogen hypothesis holds that obesogen exposure is 
an under-recognized and understudied factor in the obesity pandemic 
(reviewed in 23,24). While the obesogen hypothesis was initially 
controversial, many chemicals known to be obesogenic in animal 
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/endocr/bqaa024/5739626 by U
niversity of C
alifornia, Irvine user on 19 February 2020
Ac
ce
pte
d M
an
us
cri
pt
 
6 
 
models are also associated with increased obesity prevalence, BMI, 
and body weight in humans (9). Research in this area has burgeoned 
and numerous recent reviews have summarized aspects of obesogen 
research (e.g. 8,18,25,26). It was subsequently recognized that 
obesogens may have more diverse effects on metabolism than just 
contributing to obesity; although, obesity may be a key contributor to 
such effects. These include type 2 diabetes, non-alcoholic fatty liver 
disease, and the central control of metabolism. Thus, it can be argued 
that most obesogens are a subset of a larger class of chemicals 
termed metabolism disrupting chemicals (MDCs), not all of which are 
obesogens (reviewed in 9,27). Here we summarize what is known 
about the mechanisms underlying obesogen action, discuss newly 
identified obesogens and potentially obesogenic chemicals and 
propose important areas for future research. 
Classic effects and mechanisms of obesogens  
Obesogens impact the differentiation of white adipocytes, in vitro, and 
the storage of fat, in vivo, in multiple model organisms (reviewed in 
8,9)(Figure 1). We distinguish bona fide obesogens that induce 
increased white adipose tissue (WAT) weight, in vivo, from potential 
obesogens that can induce adipogenesis, in vitro, but have not yet 
been demonstrated to induce WAT accumulation in vivo. Numerous 
potentially obesogenic compounds have been identified using in vitro 
assays that assess the ability of candidate chemicals to promote 
differentiation of established cell lines such as 3T3-L1 pre-adipocytes 
(28,29) or primary mouse and human multipotent mesenchymal 
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stromal stem cells (a.k.a., mesenchymal stem cells or MSCs) into 
mature adipocytes (29,30). Many chemicals that promote differentiation 
of white adipocytes in these assays activate PPARγ and/or RXR 
(29,30). This is not surprising because the PPARγ:RXR heterodimer is 
considered to be the “master regulator of adipogenesis” (31).  
One of the most well characterized obesogens is the organotin, 
tributyltin (TBT). Organotins are widely used in industry and to some 
extent in agriculture. Human exposure to organotins can occur via the 
diet such as seafood contaminated by TBT used in marine shipping 
applications (32), or as fungicides for paper mills and industrial water 
systems (reviewed in 33). Triphenyltin (TPT) use as a fungicide and 
miticide on high value food crops presents more opportunities for 
human exposure (34). TBT contaminates polyvinyl chloride plastics 
and organotins are found in samples of house dust (35,36). 
TBT binds to and activates PPARγ and RXR at environmentally-
relevant (nM) levels, promoting adipogenesis and lipid accumulation 
(21,22,37). Human and mouse MSCs and 3T3-L1 pre-adipocytes were 
induced to differentiate into white adipocytes via a PPARγ-dependent 
pathway after exposure to nM levels of TBT (38,39). Prenatal TBT 
exposure diverted bone marrow derived MSCs preferentially toward the 
adipose lineage and away from the bone lineage in exposed mice (39) 
and in mouse MSCs, in vitro (40).  
Prenatal and/or perinatal exposure to TBT in mice led to increased 
body fat in the offspring (22,41,42). TBT also induced obesity in mice in 
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both sexes when treated at any age (43-46). Similar effects were 
observed in rats (46), goldfish (47), and zebrafish (48,49). Therefore, 
the obesogenic effects of TBT exposure, both developmentally and in 
adulthood, are well-supported in the literature across model systems. 
Epidemiological studies of TBT exposures and effects are scant. A 
longitudinal Finnish cohort study positively associated placental TBT 
levels with infant weight gain, an established risk factor for adult 
obesity (50). A recent analysis of NHANES data revealed a strong link 
between elevated urinary total tin levels and diabetes (51). Human 
exposure to tin is ubiquitous (52) and it was just shown that plastic 
specimen containers strongly bind organotins (particularly TBT), 
sharply impairing recovery (53). Therefore, previous studies of 
organotin levels in human specimens (e.g., 54) probably substantially 
underestimated TBT levels due to their use of plastic containers during 
processing and analysis.  
A recent clinical study that strongly supports the obesogen hypothesis 
found that people with the highest blood levels of perfluorinated 
chemicals had lower resting metabolic rates and regained weight faster 
after dieting than those with the lowest levels (55). In agreement with 
predictions from rodent studies (39,40), the same group showed that 
humans with the highest blood levels of perfluoroalkyl compounds had 
lower bone mineral density at baseline and lost bone mineral density 
faster in a weight-loss trial (56). 
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Similar obesogenic effects have been observed with other 
environmental chemicals, such as phthalates, persistent organic 
pollutants (POPs), and components of plastics and epoxy resins. The 
phthalate mono-2-ethylhexyl phthalate (MEHP) induced adipogenesis 
in 3T3-L1 preadipocytes via activation of PPARγ (57). Di-2-ethylhexyl 
phthalate (DEHP) induced expression of adipogenic genes in vivo and 
an obesity phenotype in mice following perinatal exposure (58). 
Prenatal exposure to bisphenol A (BPA) has been linked to various 
adverse health effects including reproductive and behavioral issues 
(59), fat gain in mice and rats (60,61) and other metabolic outcomes 
such as type 2 diabetes (62,63). Some data support the possibility that 
BPA influences adipogenesis as a PPARγ agonist, although, BPA is a 
relatively weak activator of PPARγ, in vitro (64-66). Others proposed 
that BPA may induce its obesogenic effects indirectly via its ability to 
bind to estrogen receptors and interfere with estrogen signaling (67).  
Effects of obesogens acting through other nuclear receptors such as 
the glucocorticoid receptor, estrogen receptors and androgen receptors 
have been reported and were discussed in detail elsewhere (reviewed 
in 9,26). More recently, it has been observed that chronic 52-week 
exposure of male mice to a mixture of six pesticides commonly used in 
France, at doses equivalent to the tolerable daily intake of each 
pesticide, led to increased body weight, WAT weight, and glucose 
intolerance (68). In contrast, similarly exposed females exhibited 
elevated fasting glucose, increased ratio of reduced to oxidized 
glutathione in the liver and perturbed levels of microbiome-related 
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urinary metabolites. Loss of the xenobiotic receptor CAR prevented 
body weight gain and changes in glucose metabolism in males 
whereas females exhibited increased toxicity, higher body weights and 
elevated mortality rates in the absence of CAR (68). 
Many obesogens that have been identified using in vivo studies act 
through nuclear hormone receptor-dependent mechanisms, as do 
many of those detected using in vitro adipogenesis assays (reviewed in 
69). In addition, interaction between nuclear receptors and cross-talk 
between signaling pathways has been reported (70). However, some of 
the effects observed in vitro (29) and in vivo, especially 
transgenerational effects (25) have not been linked directly to the 
activation of particular nuclear hormone receptors. Therefore, the 
mechanisms through which these compounds act appear to be more 
complex. 
Mechanisms of Obesogen action: Beyond PPARγ 
Since many known obesogens activate PPARγ and induce 
adipogenesis, PPARγ activation is widely believed to be a major 
mechanism through which obesogens can contribute to obesity. 
PPARγ continues to be the receptor most commonly targeted in 
screening assays for obesogens (28,71,72). However, recent studies 
have demonstrated alternative and novel mechanisms of obesogen 
action. These include activation of the retinoid X receptor (RXR) to 
induce adipocyte lineage commitment and impair adipocyte health 
(73,74), activation of multiple other nuclear receptors, induction of 
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epigenetic modifications in fat tissue (75), alteration of chromatin 
accessibility or architecture (41,76), and induction of gut microbiome 
dysbiosis (77-79). Thus, obesogens have a broad and diverse 
spectrum of actions. This section discusses some PPARγ-independent 
mechanisms of obesogens action. A summary of the known and 
proposed mechanisms through which obesogens can act, together with 
their possible effects, is illustrated in Figure 1. 
Adipocyte commitment 
TBT was shown to bind to and activate RXR, which is an obligate 
heterodimeric partner for many nuclear receptors, including PPARγ 
(80). TBT, as well as selective RXR activators (rexinoids), could 
commit female mouse MSCs to the adipocyte lineage by activating 
RXR, whereas selective pharmacological activation of PPARγ could 
not (74). It was proposed that RXR activation in MSCs inhibits the 
expression of enhancer of zeste 2 (EZH2), the catalytic subunit of 
polycomb repressor complex 2 which deposits the repressive histone 3 
lysine 27 trimethylation mark (H3K27me3) on chromatin. Loss of 
H3K27me3 in TBT-treated MSCs near to genes important for adipogenic 
commitment led to increased expression of these genes, which largely 
explains the increased commitment of these MSCs toward the adipose 
lineage (74). These results also demonstrated that TBT activation of 
RXR can induce epigenomic modifications, revealing a new mode of 
action for this well-known toxicant.  
Adipocyte health 
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/endocr/bqaa024/5739626 by U
niversity of C
alifornia, Irvine user on 19 February 2020
Ac
ce
pte
d M
an
us
cri
pt
 
12 
 
Adipocytes have important functions in the maintenance of metabolic 
health, including glucose and triglyceride uptake from the bloodstream 
in response to insulin. Disruption of adipocyte function contributes to 
insulin resistance and type 2 diabetes. Sargis and colleagues first 
showed that adipocytes induced to differentiate from 3T3-L1 cells by 
TBT were functionally distinct from adipocytes induced by the PPARγ 
activator, troglitazone (81). It is generally accepted that selective 
PPARγ activators, such as troglitazone and rosiglitazone, promote the 
development of healthy white adipocytes in vitro and in vivo (82,83). 
Healthy white adipocytes are characterized by sensitivity to insulin; 
production of insulin sensitizing, anti-inflammatory adipokines such as 
adiponectin, apelin and FGF21; normoxia; and low to no expression of 
inflammatory or fibrotic marker genes. Healthy white adipocytes have 
the ability to undergo conversion to beige adipocytes when treated with 
thyroid hormone, cold exposure, or β3-adrenergic receptor agonists. 
These thermogenic adipocytes express genes such as Ucp1 to 
uncouple oxidative phosphorylation from ATP production leading to the 
production of heat (73). Activation of RXR by TBT and other rexinoids 
not only led to increased adipogenic commitment, but the adipocytes 
treated with TBT or rexinoids during differentiation from MSCs were 
dysfunctional (73). These adipocytes displayed impaired glucose 
uptake and insulin signaling, increased expression of inflammatory and 
fibrotic markers, decreased respiratory function and reduced 
expression of beige/brown adipocyte marker genes such as Ucp1, 
Elovl3, Cidea, PPARα, when stimulated with thyroid hormone (73). TBT 
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also failed to induce marker genes characteristic of thermogenic 
beige/brite adipocytes in a transcriptomal analysis of bone marrow 
derived MSCs (84). There is also some evidence that other obesogens 
can impair thermogenesis, in vivo. For example, perinatal exposure to 
the obesogen DDT led to impaired thermogenesis in the brown adipose 
tissue resulting in lower core body temperature and increased 
susceptibility to high fat diet-induced insulin resistance in adult female 
rats (85). Together, these results revealed a new mechanism for 
obesogen action independent of PPARγ activation. They also 
demonstrated that some obesogen-induced adipocytes may be 
dysfunctional, compounding the negative effects of promoting 
increased accumulation of white fat. Additional in vivo studies will be 
needed to ascertain the degree to which obesogen exposure alters 
adipocyte health and how this influences the predisposition to obesity-
related diseases.  
Gut microbiome dysbiosis 
A relatively unexplored mechanism through which obesogen exposure 
might predispose exposed individuals to obesity is via alterations to the 
gut microbiome. It is well-established that obesity is associated with 
composition of the gut microbiome (86,87). Transplant of the gut 
microbiome from obese individuals can induce obesity in germ-free 
mice (11). In contrast, transplant of the microbiome from a lean 
individual promoted a lean phenotype in similar experiments (11). 
Transplant of the microbiome from lean donors improved metabolic 
endpoints in recipients with metabolic syndrome (11,88).  
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Many xenobiotics, including known obesogens, induced changes to gut 
microbiome composition (77,89-91). For example, BPA exposure led to 
increased prevalence of Proteobacteria and Helicobacteraceae 
together with reduced Clostridia in the gut microbiota of exposed mice, 
but the study did not investigate if the altered microbiome was directly 
associated with any metabolic endpoints (89). TBT exposure was 
associated with changes to the gut microbiome in mice including 
increased prevalence of Proteobacteria, Helicobaacteraceae and 
decreased prevalence of Clostridia, Bifidobacteriaceae and 
lactobicillaceae (77). Exposure to triphenylphosphate increased 
abundance of Erysipelotrichia and Bacilli and also decreased the 
prevalence of Clostridia (79). Gut microbial dysbiosis in mice following 
exposure to triphenyl phosphate (79) or TBT (77) was associated with 
increased fat accumulation or altered lipid metabolism. However, these 
studies did not distinguish whether observed differences in the 
microbiome were the result of metabolic differences in the mice or if the 
altered microbiome induced the metabolic changes. Monitoring the 
microbiomes of the dams before and after exposure could help in 
differentiating between these possibilities, as would conducting a 
microbiome transplant into germ-free mice. It should also be noted that 
microbial metabolites have been identified as agonistic ligands for the 
aryl hydrocarbon receptor (AhR) (reviewed in 92). Promoting AhR 
activity inhibited adipogenesis (93), obesity and fatty liver in both male 
and female mice (94,95) and protected from the effects of high fat diet 
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(96). Inhibiting the expression or action of AhR promoted obesity and 
fatty liver (reviewed in 97). 
The “Western dietary pattern” is strongly associated with obesity and 
several recent studies have demonstrated that components of the 
Western diet (e.g. ultra-processed food, food additives, artificial 
sweeteners, etc.) can disrupt the gut microbiome (98). Two common 
dietary emulsifiers, carboxylmethylcellulose and P-80, were recently 
shown to induce intestinal inflammation and disrupt the gut 
microbiome, leading to metabolic syndrome in mice together with 
increased body weight and WAT depot weight (99). (See also the 
discussion below about similar emulsifiers and food additives). Taken 
together, these results suggest that disrupting the composition of the 
gut microbiome could be a new mechanism through which obesogen 
exposure can promote obesity. They also reveal common food 
additives as a new class of candidate obesogens that require further 
investigation.  
Possible mechanisms underlying transgenerational effects of 
obesogen exposure 
An intriguing result is that the effects of early life obesogen exposure 
can be transmitted to future generations. When pregnant F0 mouse 
dams were treated with TBT, F1 animals were exposed as embryos, 
and F2 were exposed as germ cells within F1. F3 and subsequent 
generations were not exposed; effects in these generations are 
considered to be transgenerational and permanent (100,101). It was 
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shown that the effects of TBT treatment on obesity were 
transgenerational and could be detected in the F1, F2, F3, and F4 
descendants of F0 mice exposed during pregnancy (42) or during 
pregnancy and lactation (41). Interestingly, transgenerational obesity 
was not observed in similar experiments using the strong PPARγ 
activator rosiglitazone; therefore, pathways in addition to PPARγ may 
be required to produce the transgenerational phenotype (42). 
Alternatively, it might be possible that the “unhealthy” adipocytes 
produced by TBT exposure are responsible for the transgenerational 
phenotypes in adipose tissue; this is a ripe area for future study. It was 
proposed that obesogen exposure can permanently reprogram MSCs 
to favor the adipose lineage (39). Gene expression in MSCs taken from 
F1-F3 generation mice after F0 exposure throughout pregnancy was 
also biased toward the adipogenic lineage (42). It was suggested that 
TBT exposure promoted epigenomic changes favoring the 
development of obesity (41); thus, this may be an example of a 
maternal programming event leading to a life-long phenotype.  
In addition to TBT, heritable effects of several environmental chemicals 
on obesity have been demonstrated, albeit at relatively high doses. 
Plastic components such as BPA, diethylhexyl and dibutyl phthalates 
(58), the pesticide methoxychlor (102), a mixed hydrocarbon mixture 
(jet fuel JP-8) (103) and the once widely used pesticide, DDT (104) all 
induced transgenerational obesity in rats, observed in the F3 and/or F4 
offspring of following ancestral prenatal or perinatal obesogen 
exposure to the F0 dams (58,101-104). The mechanisms underlying 
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these transgenerational effects remain unclear. Some proposed 
mechanisms for transgenerational effects of obesogen exposure are 
discussed in this section and illustrated in Figure 1. Transgenerational 
effects of obesogen exposure are particularly concerning because 
current risk assessment paradigms do not consider this “generational 
toxicology” (105). 
Epigenetic modifications 
Epigenetic modifications to the genome are one mechanism through 
which environmental factors, such as chemical exposure, can alter 
gene expression and lead to adverse outcomes. Many epigenetic 
modifications have been observed after obesogen exposure. For 
example, the obesogen TBT induced global changes to DNA 
methylation (106) and to histone methylation (74), in vitro. Many 
environmental chemicals, including known obesogens, led to 
epigenetic modifications in vivo and altered epigenetic signatures and 
obesity phenotypes,  in unexposed generations (58,75,103,104). It has 
been suggested that such epimutations can be inherited (58,104,107) 
and that chemical exposures during fetal development can induce 
epigenetic changes in the germline leading to observed phenotypes in 
subsequent generations (108).  
Some argue that altered DNA methylation itself may be transmitted 
across generations (109,110), but others contest these results and hold 
that DNA methylation is not readily heritable (111,112). This is because 
the zygote undergoes genome-wide erasure of epigenetic marks 
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shortly after fertilization and the developing germ cells experience an 
additional wave of global demethylation as they mature (113-115). 
These stages of global demethylation in both the zygote genome and 
in the developing germline would likely prevent inheritance of most 
altered DNA methylation marks. There is some discussion about some 
DNA methylation escaping reprogramming in an “imprinting like” 
mechanism; however, the presence of DNA methylation at particular 
sites has not been demonstrated across generations. Indeed, the 
opposite has been shown; there is little, if any consistency in DNA 
methylation across generations and among tissues in transgenerational 
experiments (75,105,116,117). The consensus from a variety of 
exposures is that altered DNA methylation can be detected in the F3 
generation and beyond in transgenerational experiments, but a 
plausible mechanism for how these changes are transmitted across 
generations is lacking. 
In addition to DNA methylation, other types of epigenetic changes have 
been observed following ancestral chemical exposure. Histone 
modifications are capable of inducing changes to chromatin packaging 
and therefore, DNA accessibility and gene expression. In the male 
germline, a majority of histones are removed during spermatogenesis. 
However, 5-15% of histones are retained in mammalian sperm. 
Analysis of the sperm of F3 rats ancestrally exposed to the pesticide 
DDT or fungicide vinclozolin revealed additional differential histone 
retention sites (DHRs) for histone H3 compared to the sperm of control 
lineage F3 animals (118). Histone retention in the sperm can be 
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/advance-article-abstract/doi/10.1210/endocr/bqaa024/5739626 by U
niversity of C
alifornia, Irvine user on 19 February 2020
Ac
ce
pte
d M
an
us
cri
pt
 
19 
 
affected by environmental toxicant exposure and might be transmitted 
to unexposed generations. However, the underlying mechanisms and 
the importance of these retention sites on the development of disease 
phenotypes require further investigation. Non-coding RNA (ncRNA) 
expression is another type of epigenetic change that has been 
observed in transgenerational experiments. Over 200 differentially 
expressed small non coding RNAs (sncRNAs) were identified in the 
sperm between F3 rats ancestrally exposed to vinclozolin compared 
with controls (119). Some of these dysregulated sncRNAs correlated 
with mRNA profiles observed in diseased tissues in animals ancestrally 
exposed to vinclozolin. Although differences in both ncRNA and DHRs 
have been observed in transgenerational experiments after exposure 
to environmental toxicants, these changes have not been linked 
mechanistically to the transgenerational obesity. 
Chromatin accessibility 
One potential explanation for how epigenomic changes are observed in 
unexposed generations was recently proposed (41,76). In this model, 
TBT exposure induced global changes to chromatin organization that 
resulted in changes in DNA methylation. Epigenetic analysis of the fat 
tissue of obese F4 male mice ancestrally exposed to the obesogen 
TBT revealed more than 10,000 regions where methylation was altered 
in four out of four animals from the TBT group vs controls. However, 
none of these regions was closely associated with the promoters of 
genes whose expression was altered in these animals. When 
methylation was analyzed in a different way, assessing larger blocks of 
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differentially methylated regions (DMRs) in genomic DNA with the 
same direction of methylation, the result was different (41). These 
regions were called isodirectionally differentially methylated blocks, or 
isoDMBs. Hypomethylated isoDMBs were associated with 
overexpression of metabolism related genes, such as leptin, in fat 
tissue of F4 mice ancestrally exposed to TBT (41). Investigation into 
chromatin accessibility of the sperm of F3 or F4 mice, revealed that the 
hypomethylated isoDMBs in the WAT coincided with decreased 
chromatin accessibility in the same regions of the sperm. (41). It was 
proposed that TBT exposure altered chromatin architecture which 
resulted in decreased chromatin accessibility of regions where genes 
important for metabolism were located producing a “thrifty phenotype” 
(41).  
A deeper analysis of liver, MSCs and WAT from the same experiment 
revealed that the transcriptomes of tissues of mice ancestrally exposed 
to TBT showed a bias in the expression of genes related to chromatin 
organization, chromosome organization and metabolic processes 
compared with the control group and that these differences spanned 
generations (F3, F4) tissue types (liver, MSCs, WAT) and ontogeny 
(mesoderm vs endoderm) (76). The authors inferred that TBT exposure 
disrupted chromatin and chromosome organization and that this 
disrupted structure was able to self-reconstruct in subsequent 
generations, much as the normal structure is able to do in controls (76). 
In this model, the disrupted chromatin structure leads to alterations in 
DNA methylation, histone retention and the expression of mRNAs as 
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well as non-coding RNAs rather than these epigenomic alterations 
being inherited directly (76). However, the molecular mechanisms 
underlying this disrupted structure and how it might self-reconstruct in 
subsequent generations remain unknown at present.  
Newly discovered obesogens (New threats) 
Obesogens have been extensively reviewed in recent years and 
several publications report and categorize known obesogens (reviewed 
in 8,26,69). Additional chemicals are being identified that may act as 
obesogens, in vitro and in vivo. This section summarizes recent 
findings concerning new potential obesogens and how their action 
(when known) compares with that of model obesogens, such as TBT.  
Dibutyltin (DBT) 
Dibutyltin (DBT) is the major breakdown product of TBT in vivo and is 
more prevalent in the environment than TBT due to its presence at 
substantial concentrations (up to 3% w/w) in polyvinyl chloride (PVC) 
plastics (120). DBT has been demonstrated to leach into drinking water 
from PVC pipes and, therefore, may produce a hazard to humans 
(121). DBT activated the same receptors as does TBT and induced 
3T3-L1 preadipocytes (122) and human and mouse MSCs to 
differentiate into adipocytes (123). In addition, perinatal exposure to 
DBT led to increased WAT weight in mice comparable to that of the 
model obesogen TBT, although a higher dose of DBT was required to 
achieve the same effect as TBT (123). Surprisingly, offspring of DBT-
exposed dams demonstrated insulin resistance, a phenotype not 
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observed with TBT exposure (123). This raises the possibility that DBT 
may engage additional cellular mechanisms to those through which 
TBT acts. The effects of DBT on other phenotypes elicited by TBT, 
such as reprogramming stem cell fate, fatty liver, impairing 
thermogenesis and transgenerational transmission have not yet been 
investigated.  
BPA analogs 
Considerable evidence on the adverse health effects of BPA exposure 
has led to efforts to produce BPA-free plastics. However, related 
chemicals such as bisphenyl S (BPS) and bisphenyl F (BPF), are often 
used to replace BPA in these new plastics as companies strive to 
develop BPA-free products but retain current manufacturing processes 
(124). The toxicity of these BPA analogs is less well understood. Some 
studies have demonstrated that these bisphenols also have endocrine 
disrupting properties similar to BPA (reviewed in 125). Interestingly, 
Bisphenol S and halogenated BPA analogs demonstrated higher 
activation of PPARγ and potency in inducing adipogenesis than did 
BPA (64,65). A recent study revealed that perinatal exposure to BPS 
elicited obesity in mice (126). Although exposure levels of BPA have 
been significantly associated with obesity incidence, levels for BPS and 
BPF were not linked with obesity in a cross-sectional study of adults 
after adjusting for lifestyle and socioeconomic factors (124). 
Interestingly, a newer longitudinal birth cohort study revealed that BPS 
and BPF were significantly associated with obesity in children (ages 6-
19), whereas BPA and total bisphenol levels were not significantly 
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associated (127). These results suggest that substituting other 
bisphenols for BPA may not be an effective strategy for mitigating the 
hazards of BPA to humans.  
Acrylamide 
Acrylamide is a chemical widely used in the manufacture of paper, dye, 
and other industrial products. It can also be formed as an unintentional 
byproduct of cooking carbohydrate-containing foods at high 
temperatures by frying, baking, or roasting, which is probably the main 
source of human exposure (128). A recent study reported that 
acrylamide exposure induced fat accumulation in male mice when fed 
a high fat diet (129). Although acrylamide apparently increased PPARγ 
expression, it was not identified as a PPARγ activator. Instead, it was 
that acrylamide acted through the MAPK and AMPK-ACC pathways 
(129). Studies in two different longitudinal birth cohort studies from 
(France) (130) and Norway (131) demonstrated that children prenatally 
exposed to higher levels of acrylamide were more likely to be born 
small for gestational age and obese at 3 years of age. Hemoglobin 
adducts of acrylamide (HbAA) and glycidamide (HbGA) were proposed 
as biomarkers of acrylamide exposure in humans. One analysis of 
NHANES data (2003-2006) demonstrated a positive association 
between HbGA levels and obesity, but a negative association between 
HbAA and obesity (132). In contrast, another analysis of NHANES data 
(2003-2004) found a negative association to obesity for HbAA and no 
association with HbGA (133). Clearly more data are required to 
establish whether or not acrylamide exposure is linked with obesity but 
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the ubiquitous exposure of the population to acrylamide from baked 
and fried foods indicates that such data will be very important.  
Surfactants 
Dioctyl sodium sulfosuccinate (DOSS), is commonly used as a dietary 
emulsifier, as a major component of an over the counter and commonly 
recommended stool softener (Colace/Docusate). DOSS was also a 
principal component in the COREXIT dispersants that were used in the 
clean-up of the Deepwater Horizon oil spill in 2010 (134). DOSS 
activated PPARγ and induced adipogenesis, in vitro (135). A recent in 
vivo mouse study showed that perinatal exposure of pregnant mouse 
dams to DOSS led to obesity in their offspring (136). A second 
commonly used surfactant (and component of COREXIT), Span-80, 
activated RXRα and induced 3T3-L1 preadipocytes to differentiate into 
adipocytes (137). When 3T3-L1 cells were treated with a combination 
of Span-80 and DOSS, adipogenic induction was greater than with 
either chemical individually (137). These results establish surfactants 
as an unexplored category of obesogens requiring further investigation. 
Since both of these chemicals are commonly used as food additives, it 
will also be interesting to test whether they impact the gut microbiome 
to induce obesity phenotypes in vivo, as other dietary emulsifiers have 
been shown to do (99). 
Food additives 
Increasing evidence has emerged linking components of the “Western 
dietary pattern” (e.g. ultra-processed, food additives, etc.) to obesity. 
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Notably, commonly used food additives have been shown to have 
obesogenic potential. The dietary emulsifiers carboxymethylcelluclose 
and P-80 (see section on microbiome) as well as DOSS and Span-80 
(see section on surfactants) induced adipogenesis in vitro and/or in 
vivo. Other food additives have also been shown to have obesogenic 
potential. The widely used food preservative 3-tert-butyl-4-
hydroxyanisole (3-BHA) induced adipocyte differentiation in 3T3-L1 
preadipocytes (138) and 3-BHA exposure increased adiposity and lipid 
plasma levels in exposed mice (139). The flavor enhancer 
monosodium glutamate (MSG) was long ago shown to be an 
obesogen, in vivo (140). Two studies showed that MSG may induce its 
adipogenic effects by impairing secretion of glucagon-like peptide-1 
(GLP-1) an important hormone regulating appetite and satiety (141) 
and/or by antagonizing androgen receptor action (142). Taken 
together, these studies provide insight into why the consumption of 
highly processed food leads to greater weight gain than consumption of 
the same number of calories from fresh foods (5,6). This is a ripe area 
for future investigation. 
Pesticides  
Many pesticides or their major breakdown products have been linked to 
obesity in animals and in humans (reviewed in 143). One example is 
DDT in rats (104) and humans (144) and its major breakdown product 
DDE in humans (145). Although DDT was banned under the Stockholm 
Convention, it persists in the environment and continues to be used in 
some countries (particularly in Africa). Methoxychlor induced obesity in 
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rats (102) and other pesticides have been identified as candidate 
obesogens. The widely used, neonicotinoid insecticide, imidacloprid, 
was recently shown to induce 3T3-L1 preadipocytes to differentiate into 
adipocytes (as measured by lipid accumulation and marker gene 
expression) (146) and to promote high-fat diet induced obesity in mice 
(147). Glyphosate, the most highly used herbicide worldwide, induced 
obesity in F2 and F3 offspring of F0 female rats exposed during 
gestation (148). The herbicide quizalofop-p-ethyl (QPE) induced 
adipogenesis in 3T3-L1 preadipocytes (149). A variety of other 
agrochemicals induced adipogenesis in 3T3-L1 preadipocytes and in 
mouse and human MSCs (29,30). Although the potential of many of 
these agrochemicals to promote obesity, in vivo, has not yet been 
explored, the intensive use of such chemicals and the widespread 
human exposure via consumption of foods indicates that such studies 
will be important to understand the contributions of agrochemical 
exposure to obesity.  
Future directions 
Although the environmental obesogen field is just 15 years old, it is 
becoming clear that chemical exposures may be important contributors 
to the obesity pandemic. Many advances have been made into 
potential mechanisms underlying obesogen action and how obesogen 
exposure may predispose humans and animals to obesity (Figure 1). 
However, we have only just scratched the surface and need to learn 
much more about the number of obesogens that exist, how they act 
and how we can best protect ourselves and future generations from 
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their harmful impacts. A combination of mechanistic studies in cell and 
animal models together with longitudinal epidemiological and 
biomonitoring studies in humans will be required for a full assessment 
of the risks and costs of these exposures to public health. Early 
estimates suggest that these costs may be substantial (150,151). 
Many of the recent discoveries regarding the mechanisms of obesogen 
action are still in the early stages and require more research to 
determine their significance in obesity susceptibility. We currently know 
very little about how obesogen exposure can interact with diet to 
promote obesity. We know that obesogens can affect composition of 
the microbiome and that microbiome composition itself can cause 
obesity. Yet we know little about how obesogen-elicited changes in the 
microbiome can contribute to obesity or whether observed changes in 
microbiome composition are the cause or consequence of obesity and 
obesogen-induced metabolic abnormalities. 
Sexually dimorphic effects of obesogens are quite common. The first 
chemical to be reported as an obesogen, in vivo, was the synthetic 
estrogen diethylstilbestrol, which elicited obesity after perinatal 
exposure only in adult female mice (152). Such effects might be 
mediated via the estrogen receptors, but this remains to be 
demonstrated. TBT elicited increased fat mass in both sexes of the F1 
generation, but obesity was only found in males of F2-F4 generations 
and it was not possible to link these effects with sex steroid receptors 
(41,42,123). Many other examples of sexually dimorphic effects of 
obesogen exposure exist in animal models (reviewed in 9). The 
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incidence of obesity is increasing in both sexes in human populations; 
however, the effect is most striking in females, particularly in the USA 
(2). We currently know very little about the etiology of these sexual 
dimorphisms beyond some indications that effects of environmental 
estrogens, such as BPA, may be expected to be more pronounced in 
females. Since most obesogens do not act via the estrogen receptors, 
it will be important to understand which pathways mediate obesogen 
action in order to formulate appropriate strategies for intervention and 
prevention. 
It will be important to understand the effects of mixtures on obesity and 
whether combined exposure of obesogens will interact in a positive or 
synergistic manner, or if they will instead cancel each other’s effects. 
Many obesogens appear to induce a variety of effects and, therefore, 
may be acting through multiple mechanisms. TBT, for example, 
activates PPARγ and RXR, but also induces epigenetic modifications 
and changes to chromatin architecture (41,76). However it is not known 
how these changes in chromatin architecture can be transmitted to 
future generations. Multiple chemicals have been demonstrated to elicit 
transgenerational effects on obesity, but we know virtually nothing 
about how these effects are carried across generations (reviewed in 
69,105). Nuclear receptor activation can lead to epigenetic alterations 
(153,154), but this connection has not yet been characterized as part of 
the mechanism-of-action of obesogens. Many studies have established 
that the microbiome can be linked to epigenetic changes (155,156), but 
it remains to be shown whether the effects of obesogen exposure on 
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the microbiome and the epigenome causally related. It is also possible 
that the impact of obesogens on the obesity pandemic could be the 
result of exposure to a combination of obesogens, each of which may 
act through a different pathway, rather than through a single pathway. 
Many studies found that chemical mixtures can induce higher receptor 
activation or stronger phenotypes (157-160). 
While we have learned quite a bit about the number and nature of 
obesogens and have gleaned clues to how some act, we know 
relatively little about the full spectrum of obesogens and their 
mechanisms of action. Understanding how obesogens act will pave the 
way for identifying new obesogens that may act through similar 
mechanisms. What is needed for EDCs in general, and obesogens in 
particular, are better screening systems that can identify likely 
candidates for in depth screening. ToxCast and Tox21 have been 
touted as the future of such screening studies but they may not be 
adequate for the task (29). It will be important to establish 
standardized, internationally harmonized screening methods that are 
reliable, robust and perform reproducibly across laboratories. The 
European Union, under its Horizon 2020 program has funded eight 
international consortia to develop such screening assays to identify 
EDCs. Three of these consortia are focused on developing methods to 
identify metabolism disrupting chemicals. Such efforts will lay the 
foundation for international efforts to identify potential EDCs and 
obesogens. Since some of these chemicals may have multi- or 
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transgenerational effects, their identification should be an urgent public 
health goal.  
Lastly, one may wonder to what extent the effects of obesogen 
exposure can be treated and whether it is possible to avoid exposure to 
such chemicals. One unfortunate consequence of living in an 
industrialized society is exposure to a plethora of synthetic chemicals. 
Despite substantial evidence for the widespread effects of EDCs on 
laboratory animals, wildlife and humans, changing public policy to limit 
exposures has proven to be difficult. No doubt it will be equally difficult 
to implement public policies designed to reduce exposure to 
obesogens. It seems to be much more likely that effective changes in 
public policy will be best implemented at the level of local cities and 
school boards where the influence of concerned citizens equals or 
exceeds that of industry lobbyists compared with the state and federal 
levels where the opposite prevails. Certainly, this has proven to be the 
case in Southern California where a number of cities and school 
districts have implemented policies to greatly reduce exposure to toxic 
chemicals, including EDCs. For the foreseeable future, the most 
effe tive approach will probably be personal action to reduce or 
eliminate our exposures. We recommend implementing a personal 
“precautionary principle” where one takes steps to eliminate EDCs and 
obesogens in our own diets, personal care products and lifestyles to 
the extent possible. The rise in availability of fresh organically grown 
foods, personal care products lacking EDCs, and cleaning products 
lacking toxic ingredients, along with an increase in movements to 
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reduce the use of single-use plastics, etc. is testimony to the powerful 
effects that our buying choices in the marketplace have on corporate 
behavior.  
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Figure Legend 
Figure 1: Diagram of known and proposed mechanisms and 
effects of obesogen exposure. Known mechanisms through which 
obesogens act are shown as a solid purple line. Proposed mechanisms 
are shown in dashed black lines. Plausible, but uninvestigated, 
interactions between obesogen actions are shown in dashed gray 
lines. Known mechanisms are described in green boxes and the 
outcomes of obesogen exposures are shown in pale red boxes. 
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